Exploring the Role of Tanezumab as a Novel Treatment for the Relief of Neuropathic Pain

Pain Medicine (United States)

Volumn 16, Issue 6, 2015, Pages 1163-1176

  Bramson, Candace ^a   Herrmann, David N ^b   Carey, William ^a   Keller, David ^a   Brown, Mark T ^a   West, Christine R ^a   Verburg, Kenneth M ^a   Dyck, Peter J ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Diabetic Peripheral Neuropathy; Nerve Growth Factor; Neuropathic Pain; Postherpetic Neuralgia; Tanezumab

Indexed keywords

NERVE GROWTH FACTOR; PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALLERGY; ALLODYNIA; ANALGESIA; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; BURNING SENSATION; CONTROLLED STUDY; COUGHING; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; FEMALE; HEADACHE; HUMAN; HYPERESTHESIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NEURALGIA; NEURITIS; NEUROPATHIC PAIN; NEUROPATHY; OROPHARYNX PAIN; PAIN ASSESSMENT; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; TOOTH ABSCESS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; VIRUS INFECTION; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; PAIN MEASUREMENT; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; DIZZINESS; DOUBLE-BLIND METHOD; HEADACHE; HUMANS; NEURALGIA; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84932195257     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12677     Document Type: Article

References (30)

1. Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011; 115:189-204.
2. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008; 17:1326-35.
3. Wild KD, Bian D, Zhu D, et al. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp Ther 2007; 322:282-7.
4. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006; 27:85-91.
5. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005; 65:9426-35.
6. Brown M, Murphy F, Radin D, et al. Tanezumab reduces osteoarthritic knee paResults of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012; 13:790-8.
7. Brown M, Murphy F, Radin D, et al. Tanezumab reduces osteoarthritic hip paResults of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013; 65:1795-803.
8. Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol 2014; 41:2249-59.
9. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011; 152:2248-58.
10. Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain 2013; 154:1009-21.
11. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for treatment of knee osteoarthritis pain. N Engl J Med. 2010; 363:1521-31.
12. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: A randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011; 19:1405-12.
13. Schnitzer TJ, Ekman EF, Spierings EL, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis, in press. doi:10.1136/annrheumdis-2013-204905.
14. Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011; 19:639-46.
15. Spierings EL, Fidelholtz J, Wolfram G, et al. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013; 154:1603-12.
16. Dyck PJ, Davies JL, Litchy WJ, O'rien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49:229-39.
17. Dyck PJ, Hughes RAC, O'Brien P. Quantitating overall neuropathic symptoms, impairments, and outcomes. Dyck PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: Elsevier; 2005:1031-51.
18. Dyck PJ, Norell JE, Tritschler H, et al. Challenges in design of multicenter trials: End points assessed longitudinally for change and monotonicity. Diabetes Care 2007; 30:2619-25.
19. Lauria G, Cornblath DR, Johansson O, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005; 12:747-58.
20. Schiffmann R, Hauer P, Freeman B, et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006; 34:53-6.
21. Brown MT, Herrmann DN, Goldstein M, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci 2014; 345:139-47.
22. McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: Normative reference range and diagnostic efficiency. Arch Neurol 1998; 55:1513-20.
23. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 1998; 12:43-55.
24. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011; 185:1716-21.
25. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9:105-21.
26. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000; 88:287-94.
27. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94:149-58.
28. Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain 2001; 94:131-2.
29. Kim HC, Cho YJ, Ahn CW, et al. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med 2009; 26:1228-34.
30. Unezaki S, Sasaki A, Mabuchi T, et al. Involvement of Tyr1472 phosphorylation of NMDA receptor NR2B subunit in postherpetic neuralgia in model mice. Mol Pain 2012; 8:59.